logo

Our Healthbox Launches at Dixon Hall, Democratizing Access to Healthcare with Support from CANFAR and BMO

Cision Canada07-05-2025
Innovative "smart" vending machine developed by St. Michael's researcher dispenses free HIV self-testing kits, harm reduction, sexual health supplies
TORONTO, May 7, 2025 /CNW/ - Toronto's first Our Healthbox has officially launched at Dixon Hall (65 Dundas Street East), with support from BMO and the Canadian Foundation for AIDS Research (CANFAR). Driven by a shared view that everyone deserves the right to what they need for their health, this new Our Healthbox will provide free access to HIV self-tests, naloxone kits, harm reduction supplies, and sexual health products.
Developed by Dr. Sean B. Rourke, Director of REACH Nexus at the MAP Centre for Urban Health Solutions at St. Michael's Hospital (Unity Health Toronto), these cutting-edge machines feature interactive touchscreens mounted on commercially available vending machines—transforming them into Our Healthbox units.
Healthboxes provide low-barrier, cost-free access to HIV self-test kits—empowering individuals to "know their status"—as well as potentially life-saving naloxone kits to reverse opioid overdoses. They also offer wellness products (such as menstrual and hygiene items, or seasonal essentials like hats and gloves), and harm reduction supplies tailored to the specific needs of each community. Each machine also includes vital health information and a service directory to help users connect with local healthcare services and supports.
Our Healthbox will play a critical role in supporting Dixon Hall, a multi-service agency that serves over 10,000 people each year—making a meaningful impact in the lives of some of the most vulnerable and at-risk members of downtown Toronto's East Side community.
By providing anonymous access to health supplies, these machines eliminate common barriers to care—ensuring individuals can get what they need, when they need it. The launch at Dixon Hall, along with a recent installation at St. Boniface Hospital in Winnipeg, have been generously supported by BMO and CANFAR.
BMO's support for the Our Healthbox program is a reflection of its Purpose, to Boldly Grow the Good in business and life.
"BMO is committed to driving progress for healthcare in the communities we serve by supporting initiatives like Our Healthbox," said Tony Tintinalli, Head, Specialized Sales, Canadian Personal Banking, BMO. "Increased access to essential healthcare supplies leads to stronger and healthier communities, to support a thriving economy."
Our Healthbox is more than a vending machine—it's a healthcare intervention. By offering vital health items in accessible locations, the initiative aims to break down barriers and significantly improve health outcomes, especially in communities with limited access to traditional healthcare.
Andy Pringle, Chair of CANFAR, said the launch of a Healthbox at Dixon Hall reinforces CANFAR's commitment to health equity and improving outcomes for marginalized populations. "CANFAR is proud and excited to be a part of the launch of Our Healthbox at Dixon Hall. With this initiative, we are helping to make vital resources available to everyone—like HIV self-test kits—no matter someone's circumstances. Our Healthbox will help normalize conversations around sexual health and reduce stigma in our communities," said Pringle.
First introduced in 2023, Our Healthbox has expanded nationwide. Thirteen machines are currently serving families and communities across Alberta, Manitoba, Ontario, and New Brunswick. Additional units are planned for Newfoundland, Nova Scotia, and the Northwest Territories.
" Our Healthbox is a huge step forward in ensuring our community members have what they need to protect their health," said Mina Mawani, CEO of Dixon Hall. "It's about giving people control over their well-being in a way that's easy and accessible."
Dixon Hall provides support to at-risk youth, seniors, individuals living with physical and mental health challenges, those experiencing housing insecurity, job seekers, and newcomers to Canada. As a frontline agency, it plays a critical role in addressing Toronto's—and Ontario's—growing homelessness crisis.
Across the province, more than 80,000 people are currently experiencing homelessness—a 25% increase since 2022, according to the Association of Ontario Municipalities.
Dr. Rourke emphasized that this initiative helps people who may be excluded from traditional healthcare due to stigma or systemic barriers.
"This is about more than just providing supplies—it's about restoring dignity and trust in healthcare," said Dr. Rourke. "Too many people are left behind because of stigma, discrimination, or simply because services aren't available where they live. Our Healthbox is a response to that. By placing these smart, community-centered machines in underserved areas, we're removing barriers and meeting people where they are—offering the tools they need to take charge of their health, on their own terms."
Beyond convenience, Our Healthbox units are equipped with real-time data analytics that monitor usage patterns to ensure product availability and inform rapid, evidence-based public health responses.
To date, the machines have been visited over 118,000 times, distributing more than 48,000 health and harm reduction supplies—including over 2,100 naloxone kits.
As the program continues to expand, its impact will only grow. Our Healthbox represents the future of accessible, community-driven healthcare—where innovative solutions meet people where they are and give them the tools they need to thrive.
In addition to BMO's support, Our Healthbox is generously funded by The Canadian Institutes of Health Research (CIHR); Public Health Agency of Canada (PHAC); TD Canada Trust, St. Michael's Foundation, The Jackman Foundation, Power To Give Foundation. Our Healthbox launches in Atlantic Canada are funded by Even the Odds, a partnership between Staples Canada and MAP Centre for Urban Health Solutions.
For more information about Our Healthbox and to find a location near you, please visit www.ourhealthbox.ca.
About REACH Nexus at MAP Centre for Urban Health Solutions
REACH Nexus is an ambitious national research group working on how to address HIV, Hepatitis C, and other sexually transmitted and blood-borne infections (STBBIs) in Canada. REACH is a part of MAP, located at St. Michael's Hospital in Toronto – Canada's largest research centre focused on health equity and the social determinants of health. REACH Nexus is focused is on reaching the undiagnosed, implementing and scaling up new testing options, strengthening connections to care, improving access to options for prevention (PrEP and PEP) and ending stigma. We work in collaboration and partnership with people living with HIV, community-based organizations, front-line service agencies, healthcare providers, public health agencies, researchers, industry partners, and federal, provincial and regional policymakers.
About CANFAR
The Canadian Foundation for AIDS Research (CANFAR) is Canada's leading independent voice for the fight against HIV/AIDS. CANFAR is committed to supporting research, education, and community outreach programs that address the prevention, treatment, and stigma surrounding HIV/AIDS.
BMO Gives. Good grows here.
Helping communities thrive by supporting the organizations that sustain them and encouraging employee giving and volunteerism is at the heart of BMO's Purpose, to Boldly Grow the Good in business and life.
In 2024, we directed more than $108 million to drive progress for communities, which included $101 million in philanthropic contributions to hundreds of charities and nonprofit organizations across North America.
Our colleagues spent over 54,000 hours volunteering in the community and contributed more than $39 million of donations through employee-driven giving in our annual campaigns.
BMO.com.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

EU regulator green lights an injectable HIV drug that could help stop transmission
EU regulator green lights an injectable HIV drug that could help stop transmission

Toronto Star

time2 days ago

  • Toronto Star

EU regulator green lights an injectable HIV drug that could help stop transmission

LONDON (AP) — The European Medicines Agency has recommended authorizing a twice-yearly injectable drug aimed at preventing HIV, which scientists say could help end the virus' transmission. In a statement on Friday, the EU drug regulator said its evaluations of lenacapavir, sold as Yeytuo in Europe by Gilead Sciences, showed the drug is 'highly effective' and 'considered to be of major public health interest.' Once the regulator's guidance is accepted by the European Commission, the authorization is valid in all 27 EU member countries as well as Iceland, Norway and Liechtenstein.

EU regulator approves injectable HIV drug lenacapavir that experts say could help stop transmission
EU regulator approves injectable HIV drug lenacapavir that experts say could help stop transmission

Toronto Sun

time2 days ago

  • Toronto Sun

EU regulator approves injectable HIV drug lenacapavir that experts say could help stop transmission

Published Jul 25, 2025 • 2 minute read The Gilead Sciences sign is seen outside their headquarters in Foster City, Calif., on April 30, 2020. Photo by JOSH EDELSON / AFP via Getty Images Reviews and recommendations are unbiased and products are independently selected. Postmedia may earn an affiliate commission from purchases made through links on this page. LONDON — The European Medicines Agency has recommended authorizing a twice-yearly injectable drug aimed at preventing HIV, which scientists say could help end the virus' transmission. This advertisement has not loaded yet, but your article continues below. THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY Subscribe now to read the latest news in your city and across Canada. Unlimited online access to articles from across Canada with one account. Get exclusive access to the Toronto Sun ePaper, an electronic replica of the print edition that you can share, download and comment on. Enjoy insights and behind-the-scenes analysis from our award-winning journalists. Support local journalists and the next generation of journalists. Daily puzzles including the New York Times Crossword. SUBSCRIBE TO UNLOCK MORE ARTICLES Subscribe now to read the latest news in your city and across Canada. Unlimited online access to articles from across Canada with one account. Get exclusive access to the Toronto Sun ePaper, an electronic replica of the print edition that you can share, download and comment on. Enjoy insights and behind-the-scenes analysis from our award-winning journalists. Support local journalists and the next generation of journalists. Daily puzzles including the New York Times Crossword. REGISTER / SIGN IN TO UNLOCK MORE ARTICLES Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account. Share your thoughts and join the conversation in the comments. Enjoy additional articles per month. Get email updates from your favourite authors. THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK. Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account Share your thoughts and join the conversation in the comments Enjoy additional articles per month Get email updates from your favourite authors Don't have an account? Create Account In a statement on Friday, the EU drug regulator said its evaluations of lenacapavir, sold as Yeytuo in Europe by Gilead Sciences, showed the drug is 'highly effective' and 'considered to be of major public health interest.' Once the regulator's guidance is accepted by the European Commission, the authorization is valid in all 27 EU member countries as well as Iceland, Norway and Liechtenstein. Last year, studies suggested that lenacapavir, already used to treat people with HIV, was nearly 100% effective in stopping transmission in both women and men. Winnie Byanyima, executive director of the UN AIDS agency, has said the drug 'could change the trajectory of the HIV epidemic' if it is made available to everyone who needs it. Your noon-hour look at what's happening in Toronto and beyond. By signing up you consent to receive the above newsletter from Postmedia Network Inc. Please try again This advertisement has not loaded yet, but your article continues below. In June, the U.S. Food and Drug Administration authorized lenacapavir to prevent HIV. Earlier this month, the World Health Organization recommended countries offer the drug as an additional option to people at risk of the virus. Condoms help guard against HIV infection if used properly. Other medication aimed at preventing HIV include daily pills that people can take and another injectable drug called cabotegravir, which is given every two months. Lenacapavir's six-month protection makes it the longest-lasting type, an option that could attract people wary of more visits to health clinics or stigma from taking daily pills. Critics have raised concerns, however, that lenacapavir may not be made widely enough available to stop global outbreaks of HIV. Drugmaker Gilead has said it will allow cheap, generic versions to be sold in 120 poor countries with high HIV rates — mostly in Africa, Southeast Asia and the Caribbean. This advertisement has not loaded yet, but your article continues below. But it has excluded nearly all of Latin America, where rates are far lower but increasing, sparking concern the world is missing a critical opportunity to stop the disease. Last year, there were about 630,000 AIDS deaths worldwide and more than 40 million people are estimated to have HIV, according to UNAIDS. UNAIDS chief Byanyima has previously suggested the U.S. President Donald Trump make a deal with Gilead to produce and licence its 'magical' prevention drug lenacapavir across the world to the millions of people who need it. For more health news and content around diseases, conditions, wellness, healthy living, drugs, treatments and more, head to – a member of the Postmedia Network. Columnists Sunshine Girls Toronto & GTA Toronto & GTA News

EU regulator approves injectable HIV drug that experts say could help stop transmission
EU regulator approves injectable HIV drug that experts say could help stop transmission

Toronto Star

time2 days ago

  • Toronto Star

EU regulator approves injectable HIV drug that experts say could help stop transmission

LONDON (AP) — The European Medicines Agency has recommended authorizing a twice-yearly injectable drug aimed at preventing HIV, which scientists say could help end the virus' transmission. In a statement on Friday, the EU drug regulator said its evaluations of lenacapavir, sold as Yeytuo in Europe by Gilead Sciences, showed the drug is 'highly effective' and 'considered to be of major public health interest.' Once the regulator's guidance is accepted by the European Commission, the authorization is valid in all 27 EU member countries as well as Iceland, Norway and Liechtenstein.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store